September 21, 2017

Lysogene announces first half 2017 financial results and business update

Stepping up the strategic development of two gene-therapy drug candidates

Strengthening the medical and operational management team

Paris, France and Cambridge, MA, US – September 19, 2017 – Lysogene (FR0013233475 – LYS), a leading clinical-stage biopharmaceutical company specializing in gene therapy technology applied to central nervous system diseases, is today reporting its results for the first half of 2017, as approved by the Board of Directors on September 15, 2017, and providing an update on activities.

Karen Aiach, Lysogene’s CEO, made the following comments: “The successful IPO in February has helped accelerating progress in terms of both our clinical operations and our management team. We achieved a number of important strategic milestones during the first half of 2017, including setting-up a unique international observational natural history study in Sanfilippo syndrome A (MPS IIIA), and signing a manufacturing agreement with a first-class contract manufacturing organization based in the US to produce our gene therapy candidate for GM1 gangliosidosis (GM1). This faster development has been supported by the expertise and enthusiasm of our team, which has been strengthened by the arrivals of Mr Philippe Mendels-Flandre, Chief Operating Officer, and Dr Sophie Olivier, Chief Medical Officer. Lysogene will continue this trajectory in the second half of 2017, as we execute the preparation for the phase II/III trial in MPS IIIA”.